- Home
- PDEX vs ACRS Comparison
PDEX vs ACRS Comparison
Compare PDEX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- ACRS
- Stock Information
- Founded
- PDEX 1978
- ACRS 2012
- Country
- PDEX United States
- ACRS United States
- Employees
- PDEX N/A
- ACRS N/A
- Industry
- PDEX Medical/Dental Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- ACRS Health Care
- Exchange
- PDEX Nasdaq
- ACRS Nasdaq
- Market Cap
- PDEX 139.1M
- ACRS 132.0M
- IPO Year
- PDEX N/A
- ACRS 2015
- Fundamental
- Price
- PDEX $42.33
- ACRS $4.32
- Analyst Decision
- PDEX Strong Buy
- ACRS Buy
- Analyst Count
- PDEX 1
- ACRS 6
- Target Price
- PDEX $52.00
- ACRS $7.20
- AVG Volume (30 Days)
- PDEX 54.9K
- ACRS 6.0M
- Earning Date
- PDEX 10-31-2024
- ACRS 11-06-2024
- Dividend Yield
- PDEX N/A
- ACRS N/A
- EPS Growth
- PDEX 1.56
- ACRS N/A
- EPS
- PDEX 1.49
- ACRS N/A
- Revenue
- PDEX $56,798,000.00
- ACRS $27,079,000.00
- Revenue This Year
- PDEX $3.05
- ACRS N/A
- Revenue Next Year
- PDEX $2.02
- ACRS N/A
- P/E Ratio
- PDEX $28.45
- ACRS N/A
- Revenue Growth
- PDEX 21.01
- ACRS 26.35
- 52 Week Low
- PDEX $15.70
- ACRS $0.77
- 52 Week High
- PDEX $49.98
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PDEX 55.37
- ACRS 74.71
- Support Level
- PDEX $41.39
- ACRS $3.67
- Resistance Level
- PDEX $47.63
- ACRS $5.17
- Average True Range (ATR)
- PDEX 3.61
- ACRS 0.47
- MACD
- PDEX -0.22
- ACRS 0.20
- Stochastic Oscillator
- PDEX 40.33
- ACRS 72.93
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.